athenex-logo_750xx739-416-0-70.jpg
Athenex, Inc. 與貸方達成協議,推動快速銷售進程
15 mai 2023 11h33 HE | Athenex, Inc.
為更好地推進事務發展,公司自願申請第 11 章破產程序 公司擁有足夠的資源支援 Athenex Pharma Solutions 的營運,並在此進程期間,完成 APD 客戶訂單 紐約布法羅, May 15, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:...
athenex-logo_750xx739-416-0-70.jpg
Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process
14 mai 2023 11h15 HE | Athenex, Inc.
To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process ...
athenex-logo_750xx739-416-0-70.jpg
Athenex 發布 2022 年第四季度及全年財務業績及業務更新
22 mars 2023 14h30 HE | Athenex, Inc.
探索一系列戰略備選方案 2022 年第四季度來自持續經營的產品銷售收入同比增長 +27%,2022 年全年增長 +33% Athenex 於 2022年第四季度應佔淨虧損為 3,420 萬美元,或每股經攤薄股份 4.28 美元,而上年同期為 1.044 億美元,或每股經攤薄股份 19.08 美元 至年底,現金、現金等價物和受限現金餘額為 3,560 萬美元 KUR-502 CAR-NKT...
athenex-logo_750xx739-416-0-70.jpg
Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update
20 mars 2023 08h00 HE | Athenex, Inc.
Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was...
athenex-logo_750xx739-416-0-70.jpg
Athenex 宣佈反向股票分割
14 févr. 2023 11h30 HE | Athenex, Inc.
紐約州布法羅市, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX),一家致力於癌症和相關疾病治療新療法的發現、開發和商業化的全球生物製藥公司今天宣佈,將於 2023 年 2 月 15 日東部時間上午 12:01 對其發行的普通股進行 1:20 的反向股票分割。從明天(2023 年 2 月 15...
athenex-logo_750xx739-416-0-70.jpg
Athenex Announces a Reverse Stock Split
14 févr. 2023 08h00 HE | Athenex, Inc.
BUFFALO, N.Y., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies...
athenex-logo_750xx739-416-0-70.jpg
Athenex 宣佈 MHRA 關於口服紫杉醇的決定
03 janv. 2023 13h28 HE | Athenex, Inc.
MHRA 僅以化學成分、生產和控制 (CMC) 問題為由拒絕了口服紫杉醇治療轉移性乳腺癌的申請Athenex 計劃要求一個獨立小組對 MHRA 的決定進行審查 MHRA 的申請補充了來自 iSPY 2 研究的安全性數據,未表現出重大臨床療效或安全性問題 紐約州布法羅, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:...
athenex-logo_750xx739-416-0-70.jpg
Athenex Announces MHRA Decision on Oral Paclitaxel
03 janv. 2023 08h00 HE | Athenex, Inc.
MHRA denies Oral Paclitaxel for metastatic breast cancer based solely on chemistry, manufacturing and control (CMC) issuesAthenex plans to request a review of the MHRA decision by an independent panel...
athenex-logo_750xx739-416-0-70.jpg
Athenex 宣布 Quantum Leap Healthcare Collaborative 報告口服紫杉醇聯合 PD-1 和卡鉑在乳腺癌新輔助治療中的 I-SPY2 試驗結果顯著
20 déc. 2022 12h14 HE | Athenex, Inc.
紐約水牛城, Dec. 21, 2022 (GLOBE NEWSWIRE) --  Athenex, Inc., (NASDAQ: ATNX),一家致力於癌症及相關疾病新療法的發現、開發和商業化的全球性生物製藥公司今日宣布,其在 Quantum Leap Healthcare Collaborative 的合作者報告稱公司的口服紫杉醇聯合 encequidar 與 PD-1...
athenex-logo_750xx739-416-0-70.jpg
Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer
20 déc. 2022 08h15 HE | Athenex, Inc.
BUFFALO, N.Y., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies...